Baylor College of Medicine, Department of Pediatrics, Texas Children's Hospital, Texas Children's Cancer Center, Houston, Texas, USA.
Department of Paediatrics, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30565. doi: 10.1002/pbc.30565. Epub 2023 Jul 14.
Pediatric non-Hodgkin lymphoma (NHL) includes over 30 histologies (many with subtypes), with approximately 800 cases per year in the United States. Improvements in survival in NHL over the past 5 decades align with the overall success of the cooperative trial model with dramatic improvements in outcomes. As an example, survival for advanced Burkitt lymphoma is now >95%. Major remaining challenges include survival for relapsed and refractory disease and long-term morbidity in NHL survivors. Langerhans cell histiocytosis (LCH) was added to the NHL Committee portfolio in recognition of LCH as a neoplastic disorder and the tremendous unmet need for improved outcomes. The goal of the Children' Oncology Group NHL Committee is to identify optimal cures for every child and young adult with NHL (and LCH). Further advances will require creative solutions, including engineering study groups to combine rare populations, biology-based eligibility, alternative endpoints, facilitating international collaborations, and coordinated correlative biology.
儿科非霍奇金淋巴瘤（NHL）包含 30 多种组织学类型（许多有亚型），在美国每年约有 800 例。过去 5 十年中 NHL 生存率的提高与合作试验模式的整体成功一致，其结果显著改善。例如，晚期伯基特淋巴瘤的生存率现在>95%。主要的遗留挑战包括复发和难治性疾病的生存率以及 NHL 幸存者的长期发病率。朗格汉斯细胞组织细胞增生症（LCH）被添加到 NHL 委员会的投资组合中，以认识到 LCH 是一种肿瘤性疾病，以及改善结果的巨大未满足需求。儿童肿瘤学组 NHL 委员会的目标是为每个患有 NHL（和 LCH）的儿童和年轻成人找到最佳的治愈方法。进一步的进展将需要创造性的解决方案，包括工程研究小组来合并罕见人群、基于生物学的资格标准、替代终点、促进国际合作以及协调相关生物学。
